Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insmed (INSM) Other Non-Current Assets (2016 - 2026)

Insmed's Other Non-Current Assets history spans 16 years, with the latest figure at $99.3 million for Q1 2026.

  • Quarterly Other Non-Current Assets rose 10.6% to $99.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $99.3 million through Mar 2026, up 10.6% year-over-year, with the annual reading at $97.4 million for FY2025, 4.45% up from the prior year.
  • Other Non-Current Assets came in at $99.3 million for Q1 2026, up from $97.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $99.3 million in Q1 2026 to a low of $57.2 million in Q1 2022.
  • The 5-year median for Other Non-Current Assets is $89.8 million (2025), against an average of $85.6 million.
  • Year-over-year, Other Non-Current Assets skyrocketed 49.25% in 2022 and then fell 6.21% in 2025.
  • Insmed's Other Non-Current Assets stood at $76.1 million in 2022, then rose by 26.9% to $96.6 million in 2023, then decreased by 3.47% to $93.2 million in 2024, then rose by 4.45% to $97.4 million in 2025, then grew by 1.95% to $99.3 million in 2026.
  • Per Business Quant, the three most recent readings for INSM's Other Non-Current Assets are $99.3 million (Q1 2026), $97.4 million (Q4 2025), and $91.6 million (Q3 2025).